keyword
MENU ▼
Read by QxMD icon Read
search

renal carcinoma

keyword
https://www.readbyqxmd.com/read/28316213/-expression-of-lim-and-sh3-protein-1-in-renal-clear-cell-carcinoma-and-its-effects-on-invasion-and-migration-of-renal-clear-cell-carcinoma-786-o-cells
#1
B Jin, L Gao, W Li, J C Chen, R M Wen, J Q Wang
Objective: To investigate the expression of LIM and SH3 protein 1 (LASP1) in renal cell carcinoma and its significance in the invasion and migration of renal clear cell carcinoma 786-O cell line. Methods: The expression level of LASP1 in 41 cases of renal cell carcinoma tissues and normal renal tissues was analyzed by immunohistochemistry. The relationship between the expression level of LASP1 and clinical characteristics was further analyzed. Expression of LASP1 in 10 cases of tumor tissues with or without lymph node metastasis was analyzed by Western blot...
March 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28315906/nineteen-cases-with-synchronous-multiple-primary-cancers-studied-by-18-f-fdg-pet-ct
#2
Lifang Pang, Guobing Liu, Hongcheng Shi, Pengcheng Hu, Beilei Li, Dengfeng Cheng
OBJECTIVE: To evaluate the value of fluorine -18-fuoro-2-deoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in evaluating synchronous multiple primary cancers (SMPC). METHODS: Nineteen patients with pathologically-confirmed SMPC were collected. Clinical and (18)F-FDG PET/CT characteristics of these patients were reviewed and analyzed. Maximum standardized uptake value, (SUVmax) of all lesions was measured and difference (Δ)SUVmax between the SUV of two primary tumors in each patient was calculated as: [(the larger SUVmax - the smaller SUVmax)/ the larger SUVmax]×100%...
March 20, 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28315535/high-dose-interleukin-2-evaluation-of-a-standardized-order-set-for-biotherapy-in-an-intensive-care-unit%C3%A2
#3
Rusticio Portillas, Barbara Turner, Audrey Jeffers, Lee-Lynn Chen, Mary Champagne
BACKGROUND: Life-threatening toxicity may result from administration of high-dose (HD) interleukin-2 (IL-2). Patients receiving HD IL-2 treatment often experience severe adverse side effects, which result in the interruption of treatment. 
. OBJECTIVES: A standardized order set (SOS) was developed for patients with melanoma or renal cell carcinoma receiving HD IL-2. The aims of the study were to determine compliance of clinicians to the SOS, report the completed doses and major side effects of HD IL-2, and document the satisfaction level of clinicians...
April 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28315424/diagnostic-criteria-for-oncocytic-renal-neoplasms-a-survey-of-urologic-pathologists
#4
Sean R Williamson, Ramya Gadde, Kiril Trpkov, Michelle S Hirsch, John R Srigley, Victor E Reuter, Liang Cheng, L Priya Kunju, Ravi Barod, Craig G Rogers, Brett Delahunt, Ondrej Hes, John N Eble, Ming Zhou, Jesse K McKenney, Guido Martignoni, Stewart Fleming, David J Grignon, Holger Moch, Nilesh S Gupta
Renal oncocytoma and chromophobe renal cell carcinoma (RCC) have been long recognized as distinct tumors; however, it remains unknown if uniform diagnostic criteria are used to distinguish these tumor types in practice. A survey was distributed to urologic pathologists regarding oncocytic tumors. Responses were received from 17/26 invitees. Histologically, >1 mitotic figure was regarded as most worrisome (n=10) or incompatible (n=6) with oncocytoma diagnosis. Interpretation of focal nuclear wrinkling, focal perinuclear clearing, and multinucleation depended on extent and did not necessarily exclude oncocytoma if minor...
March 14, 2017: Human Pathology
https://www.readbyqxmd.com/read/28315422/sfpq-psf-tfe3-renal-cell-carcinoma-rcc-a-clinicopathologic-study-emphasizing-extended-morphology-and-reviewing-the-differences-between-sfpq-tfe3-rcc-and-the-corresponding-mesenchymal-neoplasm-despite-an-identical-gene-fusion
#5
Xiao-Tong Wang, Qiu-Yuan Xia, Hao Ni, Sheng-Bing Ye, Rui Li, Xuan Wang, Shan-Shan Shi, Xiao-Jun Zhou, Qiu Rao
Xp11 translocation renal cell carcinoma (RCC) with SFPQ/PSF-TFE3 gene fusion is a rare epithelial tumor. Of note, the appearance of the gene fusion does not necessarily mean that it is renal cell carcinoma. The corresponding mesenchymal neoplasms, including Xp11 neoplasm with melanocytic differentiation, TFE3 rearrangement-associated perivascular epithelioid cell tumor (PEComa) and melanotic Xp11 translocation renal cancer, can also harbor the identical gene fusion. However, the differences between Xp11 translocation RCC and the corresponding mesenchymal neoplasm have only recently been described...
March 14, 2017: Human Pathology
https://www.readbyqxmd.com/read/28314973/-should-cytoreductive-nephrectomy-be-performed-in-patients-with-metastatic-renal-cell-carcinoma-and-what-is-the-scientific-rationale
#6
N Gilbert, A S Merseburger, M W Kramer
Between 15 and 20% of patients diagnosed with renal cell carcinoma suffer from metastatic disease by the time of diagnosis. In the immunotherapy era, the standard treatment was to perform cytoreductive nephrectomy (CN) followed by treatment with interferon α. This was based on two prospective randomized trials and their combined analysis. Since the introduction of targeted therapy, the use of CN came into question and the number of performed CN has declined. Two trials (CARMENA and SURTIME) evaluating the role of CN in the times of targeted therapy have either closed early or are recruiting slowly and will probably not be able to answer this question...
March 17, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28314970/-is-surgical-treatment-ever-indicated-in-metastatic-renal-cell-carcinoma-and-if-so-based-on-which-scientific-rationale
#7
M Burger
BACKGROUND: Metastasis is a common event in renal cell carcinoma. Surgical resection of metastases may be feasible in two scenarios: aiming at palliation, which may be feasible due to reduced radiosensitivity of renal cell cancer, and aiming at prolonging survival, which may be feasible given the rather good prognosis of some patterns of metastasis. OBJECTIVE: This review intends to reflect on current evidence for surgical resection of metastases in both scenarios...
March 17, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28314968/-when-is-cytoreductive-nephrectomy-not-beneficial-for-patients-with-metastatic-renal-cell-carcinoma
#8
Martin Schostak
Primary tumor resection in patients with synchronous metastatic renal cell carcinoma and a good performance status corresponds to a guideline recommendation which, however, is based on weak data from the era of cytokine therapy. This article presents arguments that weigh heavily against cytoreductive nephrectomy. From a molecular genetic viewpoint, the intervention eliminates only the easiest adversary but cannot prevent cancer-related death. Therefore, benefits and risks must be carefully and critically considered...
March 17, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28314682/hereditary-leiomyomatosis-and-renal-cell-cancer-syndrome-an-update-and-review
#9
REVIEW
Viral M Patel, Marc Z Handler, Robert A Schwartz, W Clark Lambert
Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome is a rare genetic disorder that predisposes individuals to multiple cutaneous leiomyomas, renal cell carcinomas, and in women, uterine leiomyomas. Also known as Reed syndrome, it is caused by a germline heterozygous mutation of the fumarate hydratase tumor suppressor gene. HLRCC is associated with significant morbidity because of pain from cutaneous and uterine leiomyomas, the cutaneous pain often of unique character. Although genetic testing is currently considered the criterion standard to diagnose HLRCC, newer immunohistochemistry markers may provide rapid and cost effective alternatives to genetic testing...
March 14, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28314541/risk-of-subsequent-primary-kidney-cancer-after-another-malignancy-a-population-based-study
#10
Omar Abdel-Rahman
BACKGROUND: Population-based data on the development of kidney cancer as a second malignant neoplasm following the diagnosis of other common malignancies are rare. This clinical scenario has been evaluated within the Surveillance, Epidemiology, and End Results (SEER) database. MATERIALS AND METHODS: The SEER-9 database (1973-2013) was queried using the SEER*Stat program to determine the standardized incidence ratios (SIRs) of kidney cancer development following each one of 10 common invasive malignancies (colorectal, breast, prostate, lung, thyroid, corpus uteri, urinary bladder, kidney/renal pelvis, cutaneous melanoma, and non-Hodgkin lymphoma)...
February 27, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28314525/intraoperative-electromagnetic-navigational-bronchoscopic-localization-of-small-deep-or-subsolid-pulmonary-nodules
#11
Abbas Abbas, Sagar Kadakia, Vishnu Ambur, Kimberly Muro, Larry Kaiser
BACKGROUND: Localizing small or deep pulmonary nodules or subsolid ground-glass opacities often is difficult during video-assisted thoracoscopic surgery (VATS) or robotic-assisted thoracoscopic surgery (RATS). This can result in larger resections or conversion to thoracotomy. The goal of this study is to evaluate the role of electromagnetic navigational bronchoscopic localization (ENBL) as a safe and accurate intraoperative method to localize small, deep, or subsolid nodules. METHODS: This is a single-institution, single-surgeon retrospective study of all patients (51) who underwent combined ENBL and resection of 54 nodules between May 2013 and August 2015...
February 7, 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28314474/sulforaphane-as-an-adjunctive-to-everolimus-counteracts-everolimus-resistance-in-renal-cancer-cell-lines
#12
Eva Juengel, Stephanie Euler, Sebastian Maxeiner, Jochen Rutz, Saira Justin, Frederik Roos, Wael Khoder, Karen Nelson, Wolf O Bechstein, Roman A Blaheta
BACKGROUND: The mechanistic target of rapamycin (mTOR) inhibitors, everolimus and temsirolimus, have widened therapeutic options to treat renal cell carcinoma (RCC). However, chronic treatment with these inhibitors often induces resistance, leading to therapeutic failure. PURPOSE: The natural compound, sulforaphane (SFN), was added to an everolimus based regime in vitro in the hopes of preventing resistance development. METHODS: A panel of RCC cell lines (A498, Caki-1, KTCTL-26) was treated with everolimus or SFN or with an everolimus-SFN-combination, either short- (24h) or long-term (8 weeks), and cell growth, proliferation, apoptosis, and cell cycle phases were measured...
April 15, 2017: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://www.readbyqxmd.com/read/28314328/comparison-of-tyrosine-kinase-inhibitor-versus-mammalian-target-of-rapamycin-inhibitor-as-second-line-molecular-targeted-therapy-for-patients-with-poor-risk-metastatic-renal-cell-carcinoma
#13
Hideaki Miyake, Satoshi Imai, Keita Tamura, Takayuki Sugiyama, Hiroshi Furuse, Seiichiro Ozono, Masato Fujisawa
AIM: The objective of this study was to compare the efficacies of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORI) as second-line molecular-targeted therapy in patients with poor-risk metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: This study included 89 consecutive patients with mRCC who were classified into a poor-risk group after the failure of first-line molecular-targeted agent and subsequently received second-line targeted therapy...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28314264/targeting-the-unfolded-protein-response-as-a-potential-therapeutic-strategy-in-renal-carcinoma-cells-exposed-to-cyclosporine-a
#14
Sandra Bodeau, Chloé Sauzay, Rémy Nyga, Christophe Louandre, Véronique Descamps, Catherine François, Corinne Godin, Gabriel Choukroun, Antoine Galmiche
BACKGROUND/AIM: Organ transplant patients treated with the immunosuppressive drug cyclosporine A often present malignant kidney tumors. Cyclosporine A can promote oncogenesis in a cell-intrinsic manner by increasing the production of vascular endothelial growth factor (VEGF). MATERIALS AND METHODS: We explored the impact of cyclosporine A and the role of the unfolded protein response (UPR) on three human renal cell carcinoma (RCC) cell lines under normoxic and hypoxic (1% O2) conditions...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28304214/retroperitoneal-laparoscopic-partial-nephrectomy-for-tumors-larger-than-7%C3%A2-cm-in-renal-cell-carcinoma-initial-experience-of-single-institution
#15
Erlin Song, Xin Ma, Ruihua An, Peng Zhang, Xu Zhang, Baojun Wang, Taoping Shi, Shengkun Sun
BACKGROUND: To report our initial experience dealing with retroperitoneal laparoscopic partial nephrectomy (LPN) for tumors larger than 7 cm in renal cell carcinoma (RCC). MATERIALS AND METHODS: A total of 15 patients with malignant tumors larger than 7 cm underwent retroperitoneal LPN at our institution. Patient baseline demographics, perioperative outcomes, pathological characteristics, and estimated glomerular filtration rate (eGFR) were analyzed retrospectively in our collected database...
March 17, 2017: Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A
https://www.readbyqxmd.com/read/28303767/immunomonitoring-reveals-interruption-of-anergy-after-vaccination-in-a-case-of-type-2-papillary-renal-cell-carcinoma
#16
Maria A Clavijo-Salomon, Patricia C Bergami-Santos, José Alexandre M Barbuto
With the enormous and growing interest in the clinical application of immunotherapy, we are currently facing the need to accurately monitor the immune function of cancer patients. Here, we describe changes in the immune status of a patient with metastatic type-2-papillary renal cell carcinoma, before and after surgery and subsequent immunotherapy with a dendritic cell-tumor cell hybrid vaccine. Through the accurate assessment of monocyte-derived dendritic cells (Mo-DCs) function, we show that Mo-DCs were freed from tumor-induced maturation blockage by tumor resection surgery, while Mo-DCs-tumor induced suppression and anergy were only interrupted by the vaccination treatment...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28303494/current-management-strategy-for-metastatic-renal-cell-carcinoma-and-future-directions
#17
REVIEW
Hussein Merza, Marijo Bilusic
PURPOSE OF REVIEW: Major strides have been made in the treatment of kidney cancer in the last several years with checkpoint immunotherapies and novel targeted agents. This manuscript will review current treatment strategies for metastatic renal cell carcinoma and will discuss future directions. RECENT FINDINGS: Most recently, several new drugs including nivolumab, cabozantinib, and a combination of lenvatinib and everolimus have demonstrated acceptable toxicity and significantly improved overall survival, but evidence-based guidelines for sequencing of the approved treatment options and treatment selection based on biomarkers are still missing...
April 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28301684/economic-evaluation-of-nivolumab-as-a-second-line-treatment-for-advanced-renal-cell-carcinoma-from-us-and-chinese-perspectives
#18
Xiao Min Wan, Liu Bao Peng, Jin An Ma, Yuan Jian Li
BACKGROUND: Nivolumab is a new standard of care for patients with metastatic renal cell carcinoma (mRCC) and provides an overall survival benefit of 5.40 months in comparison with everolimus. This study evaluated the cost-effectiveness of nivolumab for the second-line treatment of mRCC from the perspective of US payers and identified the range of drug costs for which the addition of nivolumab to standard therapy could be considered cost-effective from a Chinese perspective. METHODS: A partitioned survival model was constructed to estimate lifetime costs, life-years, and quality-adjusted life-years (QALYs)...
March 16, 2017: Cancer
https://www.readbyqxmd.com/read/28300276/reassessing-the-clinical-spectrum-associated-with-hereditary-leiomyomatosis-and-renal-cell-carcinoma-syndrome-in-french-fh-mutation-carriers
#19
Marie Muller, Sophie Ferlicot, Marine Guillaud-Bataille, Gwénaël Le Teuff, Catherine Genestie, Sophie Deveaux, Abdelhamid Slama, Nicolas Poulalhon, Bernard Escudier, Laurence Albiges, Nadem Soufir, Marie-Françoise Avril, Betty Gardie, Carolina Saldana, Yves Allory, Anne-Paule Gimenez-Roqueplo, Brigitte Bressac-de Paillerets, Stéphane Richard, Patrick R Benusiglio
We addressed uncertainties regarding Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) by exploring all French cases, representing the largest series to date. Fumarate Hydratase (FH) germline testing was performed with Sanger sequencing and qPCR/MLPA. Enzyme activity was measured when necessary. We carried out whenever possible a pathology review of RCC and S-(2-succino)-cysteine (2SC)/fumarate hydratase immunohistochemistry. We estimated survival using non-parametric Kaplan-Meier. There were 182 cases from 114 families...
March 16, 2017: Clinical Genetics
https://www.readbyqxmd.com/read/28298953/cellular-preoxygenation-partially-attenuates-the-antitumoral-effect-of-cisplatin-despite-highly-protective-effects-on-renal-epithelial-cells
#20
Bahram Rasoulian, Ayat Kaeidi, Maryam Rezaei, Zahra Hajializadeh
Our previous in vitro studies demonstrated that oxygen pretreatment significantly protects human embryonic renal tubular cell against acute cisplatin- (CP-) induced cytotoxicity. The present study was designed to investigate whether this protective effect is associated with decreasing therapeutic effects of cisplatin on malignant cells. For this purpose, cultured human embryonic kidney epithelial-like (AD293), cervical carcinoma epithelial-like (Hela), and ovarian adenocarcinoma epithelial-like (OVCAR-3) cells were subjected to either 2-hour pretreatment with oxygen (≥90%) or normal air and then to a previously determined 50% lethal dose of cisplatin for 24 hours...
2017: Oxidative Medicine and Cellular Longevity
keyword
keyword
21147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"